Stephen Dewhurst, Ph.D. and Linda Whetter, D.V.M., Ph.D.

Department of Microbiology and Immunology, and Cancer Center, University of Rochester Medical Center, Rochester NY

Received 2/21/97; Accepted 2/25/97; On-line 3/1/97

6. References

1. T.C. Quinn: Global burden of the HIV pandemic. Lancet 348, 99-106 (1996)

2. S. Dewhurst, H.A. Gelbard & S.M. Fine: Neuropathogenesis of AIDS. Mol. Med. Today 2, 16-23 (1996)

3. G. Pantaleo, S. Menzo, M. Vaccarezza, C. Graziosi, O.J. Cohen, J.F. Demarest, D. Montefiori, J.M. Orenstein, C. Fox, L.K. Schrager, J.B. Margolick, S. Buchbinder, J.V. Giorgi & A.S. Fauci: Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N. Engl. J. Med. 332, 209-16 (1995)

4. Y. Cao, L. Qin, L. Zhang, J. Safrit & D.D. Ho: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N. Engl. J. Med. 332, 201-8 (1995)

5. S.P. Buchbinder, M.H. Katz, N.A. Hessol, P.M. O'Malley & S.D. Holmberg: Long-term HIV-1 infection without immunologic progression. Aids 8, 1123-8 (1994)

6. F. Kirchhoff, T.C. Greenough, D.B. Brettler, J.L. Sullivan & R.C. Desrosiers: Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332, 228-32 (1995)

7. N.J. Deacon, A. Tsykin, A. Solomon, K. Smith, M. Ludford-Menting, D.J. Hooker, D.A. McPhee, A.L. Greenway, A. Ellett, C. Chatfield, V.A. Lawson, S. Crowe, A. Maerz, S. Sonza, J. Learmont, J.S. Sullivan, A. Cunningham, D. Dwyer, D. Dowton & J. Mills: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988-91 (1995)

8. D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard & M. Markowitz: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-6 (1995)

9. X. Wei, S.K. Ghosh, M.E. Taylor, V.A. Johnson, E.A. Emini, P. Deutsch, J.D. Lifson, S. Bonhoeffer, M.A. Nowak, B.H. Hahn, M.S. Saag & G.M. Shaw: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-22 (1995)

10. A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard & D.D. Ho: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-6 (1996)

11. J.M. Coffin: HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483-9 (1995)

12. J.M. Coffin: HIV viral dynamics. AIDS 10 (suppl 3), S75-S84 (1996)

13. J.W. Mellors, C.R. Rinaldo, Jr., P. Gupta, R.M. White, J.A. Todd & L.A. Kingsley: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-70 (1996)

14. M.S. Saag, M. Holodniy, D.R. Kuritzkes, W.A. O'Brien, R. Coombs, M.E. Poscher, D.M. Jacobsen, G.M. Shaw, D.D. Richman & P.A. Volberding: HIV viral load markers in clinical practice. Nature Med. 2, 625-9 (1996)

15. M.T. Wong, M.J. Dolan, E. Kozlow, R. Doe, G.P. Melcher, D.S. Burke, R.N. Boswell & M. Vahey: Patterns of virus burden and T cell phenotype are established early and are correlated with the rate of disease progression in human immunodeficiency virus type 1-infected persons. J. Infect. Dis. 173, 877-87 (1996)

16. A. De Rossi, S. Masiero, C. Giaquinto, E. Ruga, M. Comar, M. Giacca & L. Chieco-Bianchi: Dynamics of viral replication in infants with vertically acquired human immunodeficiency virus type 1 infection. J. Clin. Invest. 97, 323-30 (1996)

17. D.D. Ho: Time to hit HIV, early and hard. N. Engl. J. Med. 333, 450-1 (1995)

18. S. Kinloch-De Loes, B.J. Hirschel, B. Hoen, D.A. Cooper, B. Tindall, A. Carr, J.H. Saurat, N. Clumeck, A. Lazzarin, L. Mathiesen, F. Raffi, F. Antunes, J. von Overbeck, R. Luthy, M. Glauser, D. Hawkins, C. Baumberger, S. Yerly, T.V. Perneger & L. Perrin: A controlled trial of zidovudine in primary human immunodeficiency virus infection. N. Engl. J. Med. 333, 408-13 (1995)

19. A.T. Haase, K. Henry, M. Zupancic, G. Sedgewick, R.A. Faust, H. Melroe, W. Cavert, K. Gebhard, K. Staskus, Z.-Q. Zhang, P.J. Dailey, H.H. Balfour, A. Erice & A.S. Perelson: Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274, 985-9 (1996)

20. M. Eigen: Viral quasispecies. Scientific American 269, 42-9 (1993)

21. J.J. Holland, J.C. De La Torre & D.A. Steinhauer: RNA virus populations as quasispecies. Curr. Top. Microbiol. Immunol. 176, 1-20 (1992)

22. S.M. Wolinsky, B.T. Korber, A.U. Neumann, M. Daniels, K.J. Kunstman, A.J. Whetsell, M.R. Furtado, Y. Cao, D.D. Ho, J.T. Safrit & J.A. Koup: Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 272, 537-42 (1996)

23. V.V. Lukashov, C.L. Kuiken & J. Goudsmit: Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period. J. Virol. 69, 6911-6 (1995)

24. M.A. Nowak, R.M. Anderson, A.R. McLean, T.F. Wolfs, J. Goudsmit & R.M. May: Antigenic diversity thresholds and the development of AIDS. Science 254, 963-9 (1991)

25. P. Borrow, H. Lewicki, X. Wei, M.S. Horwitz, N. Peffer, H. Meyers, J.A. Nelson, J.E. Gairin, B.H. Hahn, M.B.A. Oldstone & G.M. Shaw: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-11 (1997)

26. P.J.R. Goulder, R.E. Phillips, R.A. Colbert, S. McAdam, G. Ogg, M.A. Nowak, P. Giangrande, G. Luzzi, B. Morgan, A. Edwards, A.J. McMichael & S. Rowland-Jones: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Med. 3, 212-7 (1997)

27. N. Sullivan, Y. Sun, J. Li, W. Hofmann & J. Sodroski: Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J. Virol. 69, 4413-22 (1995)

28. J.P. Moore, Y. Cao, L. Qing, Q.J. Sattentau, J. Pyati, R. Koduri, J. Robinson, C.F.r. Barbas, D.R. Burton & D.D. Ho: Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J. Virol. 69, 101-9 (1995)

29. P.J. Klasse & J.P. Moore: Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1. J. Virol. 70, 3668-77 (1996)

30. D.C. Montefiori, G. Pantaleo, L.M. Fink, J.T. Zhou, J.Y. Zhou, M. Bilska, G.D. Miralles & A.S. Fauci: Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J. Infect. Dis. 173, 60-7 (1996)

31. D.J. Blackbourn, C.E. Mackewicz, E. Barker, T.K. Hunt, B. Herndier, A.T. Haase & J.A. Levy: Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc. Natl. Acad. Sci. USA 93, 13125-30 (1996)

32. G. Pantaleo, J.F. Demarest, T. Schacker, M. Vaccarezza, O.J. Cohen, M. Daucher, C. Graziosi, S.S. Schnittman, T.C. Quinn, G.M. Shaw, L. Perrin, G. Tambussi, A. Lazzarin, R.P. Sekaly, H. Soudeyns, L. Corey & A.S. Fauci: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl. Acad. Sci. USA 94, 254-8 (1997)

33. C.M. Walker, D.J. Moody, D.P. Stites & J.A. Levy: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563-6 (1986)

34. F. Cocchi, A.L. DeVico, A. Garzino-Demo, S.K. Arya, R.C. Gallo & P. Lusso: Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 270, 1811-5 (1995)

35. G. Alkhatib, C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, P.M. Murphy & E.A. Berger: CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272, 1955-8 (1996)

36. T. Dragic, V. Litwin, G.P. Allaway, S.R. Martin, Y. Huang, K.A. Nagashima, C. Cayanan, P.J. Maddon, R.A. Koup, J.P. Moore & W.A. Paxton: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381, 667-73 (1996)

37. H. Deng, R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Sutton, C.M. Hill, C.B. Davis, S.C. Peiper, T.J. Schall, D.R. Littman & N.R. Landau: Identification of a major co-receptor for primary isolates of HIV-1. Nature 381, 661-6 (1996)

38. H. Choe, M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard & J. Sodroski: The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85, 1135-48 (1996)

39. L. Wu, N.P. Gerard, R. Wyatt, H. Choe, C. Parolin, N. Ruffing, A. Borsetti, A.A. Cardoso, E. Desjardin, W. Newman, C. Gerard & J. Sodroski: CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384, 179-83 (1996)

40. A. Trkola, T. Dragic, J. Arthos, J.M. Binley, W.C. Olson, G.P. Allaway, C. Cheng-Mayer, J. Robinson, P.J. Maddon & J.P. Moore: CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384, 184-7 (1996)

41. W.A. Paxton, S.R. Martin, D. Tse, T.R. O'Brien, J. Skurnick, N.L. VanDevanter, N. Padian, J.F. Braun, D.P. Kotler, S.M. Wolinsky & R.A. Koup: Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nature Med. 2, 412-7 (1996)

42. H. Schmidtmayerova, B. Sherry & M. Bukrinsky: Chemokines and HIV replication. Nature 382, 767 (1996)

43. H. Moriuchi, M. Moriuchi, C. Combadiere, P.M. Murphy & A.S. Fauci: CD8+ T-cell-derived soluble factor(s), but not beta-chemokines RANTES, MIP-1alpha, and MIP-1beta, suppress HIV-1 replication in monocyte/macrophages. Proc. Natl. Acad. Sci. USA 93, 15341-5 (1996)

44. Y. Feng, C.C. Broder, P.E. Kennedy & E.A. Berger: HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272, 872-7 (1996)

45. E. Oberlin, A. Amara, F. Bacherlie, F. Arenzana-Seisdedos, O. Schwartz, J.-M. Heard, I. Clark-Lewis, D.F. Legler, M. Loetscher, M. Baggiolini & B. Moser: The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature 382, 833-7 (1996)

46. C.C. Bleul, M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski & T.A. Springer: The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382, 829-33 (1996)

47. C. Cheng-Mayer, R. Liu, N.R. Landau & L. Stamatatos: Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR-5 coreceptor. J. Virol. 71, 1657-61 (1997)

48. M.T. Dittmar, A. McKnight, G. Simmons, P.R. Clapham, R.A. Weiss & P. Simmonds: HIV-1 tropism and co-receptor use. Nature 385, 495-6 (1997)

49. M. Baier, A. Werner, N. Bannert, K. Metzner & R. Kurth: HIV suppression by interleukin-16. Nature 378, 563 (1995)

50. J.W. Maciaszek, N.A. Parada, W.W. Cruikshank, D.M. Center, H. Kornfeld & G.A. Viglianti: IL-16 represses HIV-1 promoter activity. J. Immunol. 158, 5-8 (1997)

51. A.S. Fauci: Host factors and the pathogenesis of HIV-induced disease. Nature 384, 529-34 (1996)

52. A.L. Kinter, M. Ostrowski, D. Goletti, A. Oliva, D. Weissman, K. Gantt, E. Hardy, R. Jackson, L. Ehler & A.S. Fauci: HIV replication in CD4+ T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous beta-chemokines and the viral inductive effects of other endogenous cytokines. Proc. Natl. Acad. Sci. USA (1996)

53. W. Barcellini, G.P. Rizzardi, G. Poli, G. Tambussi, C. Velati, P.L. Meroni, A.G. Dalgleish & A. Lazzarin: Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Research and Human Retroviruses 12, 325-34 (1996)

54. G.P. Rizzardi, W. Barcellini, G. Tambussi, F. Lillo, M. Malnati, L. Perrin & A. Lazzarin: Plasma levels of soluble CD30, tumor necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 10, F45-F50 (1996)

55. C. Graziosi, K.R. Gantt, M. Vaccarezza, J.F. Demarest, M. Daucher, M.S. Saag, G.M. Shaw, T.C. Quinn, O.J. Cohen, C.C. Welbon, G. Pantaleo & A.S. Fauci: Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection. Proc. Natl. Acad. Sci. USA 93, 4386-91 (1996)

56. A. Cossarizza, C. Ortolani, C. Mussini, V. Borghi, G. Guaraldi, N. Mongiardo, E. Bellesia, M.G. Franceschini, B. De Rienzo & C. Franceschi: Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J. Infect. Dis. 172, 105-12 (1995)

57. D. Weissman, T.D. Barker & A.S. Fauci: The efficiency of acute infection of CD4+ T cells is markedly enhanced in the setting of antigen-specific immune activation. J. Exp. Med. 183, 687-92 (1996)

58. S. Stanley, M.A. Ostrowski, J.S. Justement, K. Gantt, S. Hedayati, M. Mannix, K. Roche, D.J. Schwartzentruber, C.H. Fox & A.S. Fauci: Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N. Engl. J. Med. 334, 1222-30 (1996)

59. S.I. Staprans, B.L. Hamilton, S.E. Follansbee, T. Elbeik, P. Barbosa, R.M. Grant & M.B. Feinberg: Activation of virus replication after vaccination of HIV-1-infected individuals. J. Exp. Med. 182, 1727-37 (1995)

60. B. Brichacek, S. Swindells, E.N. Janoff, S. Pirruccello & M. Stevenson: Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. J. Infect. Dis. 174, 1191-9 (1996)

61. M.L. Gougeon, H. Lecoeur, A. Dulioust, M.G. Enouf, M. Crouvoiser, C. Goujard, T. Debord & L. Montagnier: Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J. Immunol. 156, 3509-20 (1996)

62. C.A. Muro-Cacho, G. Pantaleo & A.S. Fauci: Analysis of apoptosis in lymph nodes of HIV-infected persons. Intensity of apoptosis correlates with the general state of activation of the lymphoid tissue and not with stage of disease or viral burden. J. Immunol. 154, 5555-66 (1995)

63. T.C. Quinn, P. Piot, J.B. McCormick, F.M. Feinsod, H. Taelman, B. Kapita, W. Stevens & A.S. Fauci: Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA 257, 2617-21 (1987)

64. A.G. Dalgleish: The immune response to HIV: potential for immunotherapy? Immunol. Today 16, 356-8 (1995)

65. A.L. Kinter, G. Poli, L. Fox, E. Hardy & A.S. Fauci: HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J. Immunol. 154, 2448-59 (1995)

66. J.M. Andrieu, W. Lu & R. Levy: Sustained increases in CD4 cell counts in asymptomatic human immunodeficiency virus type 1-seropositive patients treated with prednisolone for 1 year. J. Infect. Dis. 171, 523-30 (1995)

67. P.N. Fultz, R.S. Schwiebert, L. Su & M.M. Salter: Effects of total lymphoid irradiation on SIV-infected macaques. AIDS Res. Hum. Retrovir. 11, 1517-27 (1995)

68. W.C. Greene: Denying HIV safe haven. N. Engl. J. Med. 334, 1264-5 (1996)

69. D.B. Kohn & N. Sarver: Gene therapy for HIV-1 infection. Advances in Experimental Medicine & Biology 394, 421-8 (1996)

70. M. Caruso: Gene therapy against cancer and HIV infection using the gene encoding herpes simplex virus thymidine kinase. Mol. Med. Today 2, 212-7 (1996)

71. E.M. Poeschla & F. Wong-Staal: Gene therapy and HIV disease. AIDS Clin. Rev. 1, 1-45 (1995)

72. S.H. Bridges & N. Sarver: Gene therapy and immune restoration for HIV disease. Lancet 345, 427-32 (1995)

73. C. Ezzell: Emergence of the protease inhibitors: a better class of AIDS drugs? J. NIH Res. 8, 41-5 (Jan. 1996)

74. P.Y. Lam, P.K. Jadhav, C.J. Eyermann, C.N. Hodge, Y. Ru, L.T. Bacheler, J.L. Meek, M.J. Otto, M.M. Rayner, Y.N. Wong, C.H. Chang, P.C. Weber, D.A. Jackson, T.R. Sharpe & S. Erickson-Viitanen: Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. Science 263, 380-4 (1994)

75. A.C. Collier, R.W. Coombs, D.A. Schoenfeld, R. Bassett, A. Baruch & L. Corey: Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res. 29, 99 (1996)

76. A.C. Collier, R.W. Coombs, D.A. Schoenfeld, R.L. Bassett, J. Timpone, A. Baruch, M. Jones, K. Facey, C. Whitacre, V.J. McAuliffe, H.M. Friedman, T.C. Merigan, R.C. Reichman, C. Hooper & L. Corey: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N. Engl. J. Med. 334, 1011-7 (1996)

77. R. Gulick, J. Mellors, D. Havlir, J. Eron, C. Gonzalezi, D. McMahon, D. Richman, F. Valentine, L. Jonas, A. Meibohm, R. Chiou, P. Deutsch, E. Emini & J. Chodakewitz: Potent and sustained antiretroviral activity of indinavir (IDV) in combination with zidovudine (ZDV) and lamivudine (3TC). Abstract LB7, 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC (Jan. 28 - Feb. 1,1996)

78. R.T. D'Aquila, M.D. Hughes, V.A. Johnson, M.A. Fischl, J.P. Sommadossi, S.H. Liou, J. Timpone, M. Myers, N. Basgoz, M. Niu & M.S. Hirsch: Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann. Intern. Med. 124, 1019-30 (1996)

79. A. Molla, M. Korneyeva, Q. Gao, S. Vasavanonda, P.J. Schipper, H.M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G.R. Granneman, D.D. Ho, C.A. Boucher, J.M. Leonard, D.W. Norbeck & D.J. Kempf: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med. 2, 760-6 (1996)

80. G. Croteau, L. Doyon, D. Thibeault, G. McKercher, L. Pilote & D. Lamarre: Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J. Virol. 71, 1089-96 (1997)

81. N.K. Back, M. Nijhuis, W. Keulen, C.A. Boucher, B.O. Oude Essink, A.B. van Kuilenburg, A.H. van Gennip & B. Berkhout: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15, 4040-9 (1996)

82. W.E. Robinson, Jr., M.G. Reinecke, S. Abdel-Malek, Q. Jia & S.A. Chow: Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. USA 93, 6326-31 (1996)

83. W.G. Rice, J.G. Supko, L. Malspeis, R.W. Buckheit, Jr., D. Clanton, M. Bu, L. Graham, C.A. Schaeffer, J.A. Turpin, J. Domagala, R. Gogliotti, J.P. Bader, S.M. Halliday, L. Coren, R.C. Sowder II, L.O. Arthur & L.E. Henderson: Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270, 1194-7 (1995)

84. F. Arenzana-Seisdedos, J.-L. Virelizier, D. Rousset, I. Clark-Lewis, P. Loetscher, B. Moser & M. Baggiolini: HIV blocked by a chemokine antagonist. Nature 383, 400 (1996)

85. P.S. Moore, C. Boshoff, R.A. Weiss & Y. Chang: Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 274, 1739-44 (1996)

86. P. Lusso, P. Secchiero, R.W. Crowley, A. Garzino-Demo, Z.N. Berneman & R.C. Gallo: CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 91, 3872-6 (1994)

87. R.W. Crowley, P. Secchiero, D. Zella, A. Cara, R.C. Gallo & O. Lusso: Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes. J. Immunol. 156, 2004-8 (1996)

88. R.S. Wallis, P. Nsubuga, C. Whalen, R.D. Mugerwa, A. Okwera, D. Oette, J.B. Jackson, J.L. Johnson & J.J. Ellner: Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J. Infect. Dis. 174, 727-33 (1996)

89. B.J. Dezube & M.M. Lederman: Pentoxifylline for the treatment of HIV infection and its complications. Journal of Cardiovascular Pharmacology 25, S139-42 (1995)

90. J.D. Klausner, S. Makonkawkeyoon, P. Akarasewi, K. Nakata, W. Kasinrerk, L. Corral, R.L. Dewar, H.C. Lane, V.H. Freedman & G. Kaplan: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J.A.I.D.S. 11, 247-57 (1996)

91. E.L. Jacobson, F. Pilaro & K.A. Smith: Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. USA 93, 10405-10 (1996)

92. J.A. Kovacs, S. Vogel, J.M. Albert, J. Falloon, R.T. Davey, Jr., R.E. Walker, M.A. Polis, K. Spooner, J.A. Metcalf, M. Baseler, G. Fyfe & H.C. Lane: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350-6 (1996)

93. B.L. Levine, J.D. Mosca, J.L. Riley, R.G. Carroll, M.T. Vahey, L.L. Jagodzinski, K.F. Wagner, D.L. Mayers, D.S. Burke, O.S. Weislow, D.C. St. Louis & C.H. June: Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 272, 1939-43 (1996)

94. E. Pennisi & J. Cohen: Eradicating HIV from a patient: not just a dream? Science 272, 1884 (1996)